Current and future therapy of acromegaly

Česká verzia

Authors: Václav Hána
Authors place of work: III. interní klinika 1. LF UK a VFN v Praze
Published in the journal: Vnitř Lék 2016; 62(Suppl 3): 68-72
Category: Reviews

Summary

Acromegaly is a rare disease caused by overproduction of growth hormone, which significantly worsens quality of life and increases morbidity and mortality of patients. Modern specialized surgery, radiosurgery, radiotherapy and pharmacotherapy substantially improved therapeutical possibilities and the perspective of patients. Current therapeutic modalities enable to create individually tailored therapy for the specific patient and suppress the acromegalic activity. Novel forms of currently used active substances and even conceptually new forms of pharmacotherapy are under preparation and testing (eg. octreotide in capsules, CAM2029, Somatoprim, ATL1103).

Key words:
acromegaly – cabergoline – new drugs – pegvisomant – somatostatin analogs – therapy

Zdroje

1. Hána V, Švancara J, Bandúrová L et al. Registr selárních tumorů – RESET: diagnostika a léčba akromegalie v České a Slovenské republice v 21. století. DMEV2013; 16(4): 219–224. Dostupné z WWW: http://www.tigis.cz/images/stories/DMEV/2013/04/04_hana.pdf.

2. Rajasoorya C, Holdaway IM, Wrightson P et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41(1): 95–102.

3. Katznelson L, Laws jr. ER, Melmed S et al. Acromegaly: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(11): 3933–3951. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–2700>.

4. Netuka D, Májovský M, Masopust V et al. Intraoperative MRI during endoscopic transsphenoidal surgery of growth hormone-secreting pituitary adenomas. World Neurosurg 2016; 91: 490–496. Dostupné z DOI: <http://dx.doi.org/10.1016/j.wneu.2016.04.094>.

5. Petrossians P, Borges-Martins L, Espinoza C et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152(1): 61–66.

6. Colao A, Attanasio R, Pivonello R et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006; 91(1): 85–92.

7. Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus 2010; 29(4): E12. Dostupné z DOI: <http://dx.doi.org/10.3171/2010.7.FOCUS10124>.

8. Wattson DA, Tanguturi SK, Spiegel DY et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014; 90(3): 532–539. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijrobp.2014.06.068>.

9. Ježková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly--long-term experience. Clin Endocrinol (Oxf) 2006; 64(5): 588–595.

10. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96(5): 1327–1335. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010–2443>.

11. Pokrajac A, Frystyk J , Flyvbjerg A et al. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 2009; 160(4): 543–548. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0822>.

12. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93(8): 2957–2968. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–0027>.

13. Giustina A, Chanson P, Kleinberg D et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Rev Endocrinol 2014; 10(4): 243–248. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2014.21>.

14. Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR in the primary therapy of patients with acromegaly. Clin Endocrinol 2007; 66(6): 859–868.

15. Colao A, Bronstein MD, Freda P et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014; 99(3): 791–799. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–2480>.

16. Breitschaft A, Hu K, Hermosillo Reséndiz K et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 2014; 103(3): 458–465. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2013.12.011>.

17. Henry RR, Ciaraldi TP, Armstrong D et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98(8): 3446–3453. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–1771>.

18. Van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295): 1754–1759.

19. van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97(5): 1589–1597. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–2508>.

20. Neggers SJ, Kopchick JJ, Jørgensen JO et al. Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 2011; 164(1): 11–16. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-10–0969>.

21. Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol 2016; 12(2): 90–98. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2015.196>.

22. Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 2016; 10: 227–239. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S77999>.

23. Chieffo C, Cook D, Xiang Q et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 2013; 98(10): 4047–4054. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013–2262>.

24. Melmed S, Popovic V, Bidlingmaier M et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 2015; 100(4): 1699–1708. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–4113>.

25. Afargan M1, Janson ET, Gelerman G et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001; 142(1): 477–486.

26. Plöckinger U, Hoffmann U, Geese M et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 2012; 166(2): 223–234. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–0737>.

27. Somm E, Bonnet N, Zizzari P et al. Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology 2013; 154(11): 4237–4248. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2013–1427>.

28. Trainer PJ, Newell-Price J, Ayuk J et al. A Phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF‑I in patients with acromegaly. [abstract OR09‑1]. Presented at the Endocrine Society’s 97th Annual Meeting and Exposition (2015). Dostupné z DOI: <http://dx.doi.org/10.1530/endoabs.37.GP.19.10>.